KALA BIO, Inc.KALAEarnings & Financial Report
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmology therapies. It has a pipeline of product candidates addressing both common and rare eye diseases, targeting unmet medical needs and serving patients and healthcare providers mainly across the United States.
Revenue
$420.0K
Gross Profit
N/A
Operating Profit
$-14.6M
Net Profit
$29.1M
Gross Margin
N/A
Operating Margin
-3468.8%
Net Margin
6922.1%
YoY Growth
-86.3%
EPS
$19.25
KALA BIO, Inc. Q3 FY2022 Financial Summary
KALA BIO, Inc. reported revenue of $420.0K (down 86.3% YoY) for Q3 FY2022, with a net profit of $29.1M (up 203.4% YoY) (6922.1% margin).
Key Financial Metrics
| Total Revenue | $420.0K |
|---|---|
| Net Profit | $29.1M |
| Gross Margin | N/A |
| Operating Margin | -3468.8% |
| Report Period | Q3 FY2022 |
KALA BIO, Inc. Annual Revenue by Year
KALA BIO, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $3.9M).
| Year | Annual Revenue |
|---|---|
| 2022 | $3.9M |
KALA BIO, Inc. Quarterly Revenue & Net Profit History
KALA BIO, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2022 | $0 | — | $-12.8M | N/A |
| Q3 FY2022 | $420.0K | -86.3% | $29.1M | 6922.1% |
| Q2 FY2022 | $2.1M | -31.2% | $-28.1M | -1338.6% |
| Q1 FY2022 | $1.4M | -58.0% | $-32.9M | -2400.9% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Revenue | $1.4M | $2.1M | $420000 | $0 |
| YoY Growth | -58.0% | -31.2% | -86.3% | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Assets | $111.6M | $85.0M | $85.7M | $86.8M |
| Liabilities | $116.9M | $116.5M | $86.7M | $67.8M |
| Equity | $-5.3M | $-31.6M | $-968000 | $19.0M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Operating CF | $-24.1M | $-25.4M | $-15.7M | $-13.7M |